3SBio (SSRX) and Its Rivals Head-To-Head Survey
3SBio (NASDAQ: SSRX) is one of 49 public companies in the “Biopharmaceuticals” industry, but how does it contrast to its competitors? We will compare 3SBio to related companies based on the strength of its analyst recommendations, institutional ownership, risk, profitability, earnings, dividends and valuation.
Earnings & Valuation
This table compares 3SBio and its competitors revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|3SBio Competitors||$604.20 million||$110.82 million||-57.65|
3SBio’s competitors have higher revenue and earnings than 3SBio. 3SBio is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of current ratings and price targets for 3SBio and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Biopharmaceuticals” companies have a potential upside of 6.51%. Given 3SBio’s competitors higher possible upside, analysts plainly believe 3SBio has less favorable growth aspects than its competitors.
Insider & Institutional Ownership
44.9% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 14.9% of shares of all “Biopharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares 3SBio and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
3SBio has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Comparatively, 3SBio’s competitors have a beta of 1.20, meaning that their average share price is 20% more volatile than the S&P 500.
3SBio competitors beat 3SBio on 6 of the 11 factors compared.
3SBio Inc. is a biotechnology company in the People’s Republic of China with research and development, manufacturing, and marketing capabilities focusing on bio-pharmaceutical products. The Company recombinant, or genetically engineered, protein-based products and product candidates are designed to address markets with unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. Its principal products are EPIAO and TPIAO. In addition, it has two legacy products, Intefen and Inleusin; and an in-licensed product, Iron Sucrose Supplement. The Company focuses on its research and development efforts on both novel and validated protein-based therapeutics for the treatment of diseases in the areas of nephrology, oncology, supportive cancer care, inflammation and infectious diseases, and other selected areas. In May 2013, the Company merged with Decade Sunshine Limited and Decade Sunshine Merger Sub.
Receive News & Ratings for 3SBio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 3SBio Inc and related companies with MarketBeat.com's FREE daily email newsletter.